Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

July 25, 2022

CVD, Diabetes Spike in Acute Phase of COVID-19

News Daily News

CVD, Diabetes Spike in Acute Phase of COVID-19

July 19, 2022

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

News Daily News

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

January 31, 2019

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

News Daily News

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

Michael O'Riordan

November 26, 2018

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

December 02, 2016

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

September 28, 2016

News Daily News

Una Estrategia con Trimetazidina Reduce la NIC y la Lesión Miocárdica en Pacientes Diabéticos con ERC de Carácter entre Leve y Moderado

May 30, 2014

News Daily News

Pre-PCI Trimetazidine Strategy Reduces CIN, Myocardial Injury in Diabetic Patients with Mild-to-Moderate CKD

May 30, 2014

News Daily News

Los Subgrupos de Alto Riesgo obtienen Protección Renal de la Rosuvastatina

October 11, 2013

News Daily News

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

October 11, 2013

News Daily News

ACT Substudy: NAC Does Not Reduce Kidney Damage in Diabetic Patients

April 19, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.